Eidos Therapeutics: Differentiated Market, High Stock Price, But Solid Potential In The Long Run
(WorldNews Health)

TTR amyloidosis or ATTR is a protein misfolding disease that has received a lot of attention over the last couple of years, with the approval of Alnylam´s (ALNY) first RNAi therapy Onpattro/patirisan in this indication. A number of other therapies are in late stages, with Pfizer´s (PFE) tafamidis about to see its PDUFA in November this year. There are other companies, as a fellow Seeking Alpha author has covered: `Other competitors in the clinic include Ionis´ (NASDAQ: IONS) Tegsedi, Pfizer`s (PFE) tafamidis, Eidos` (NASDAQ: EIDX) AG10, GSK`s (NYSE: GSK) miridesap and dezamizumab combo, and Prothena`s (NASDAQ: PRTA) PRX004. Additional preclinical competition includes Intellia`s (NASDAQ:...